Replies to post #94590 on Biotech Values

[DewDiligence]

Some would likely clearly prefer more drugs than fewer though given better chance to keep variant mutations from sprouting.

A two drug-cocktail HIV will have to have to show the same barrier to resistance as Atripla in order to gain traction in the marketplace. If it can, the “fewer is better” mantra ought to be a strong angle for (GSK’s) sales reps.